Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses NTRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NTRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steven Chapman | $853,710 | $0 | $12,979,558 | $0 | $1,114,151 | $0 | $9,900 | $14,957,319 |
| Chief Executive Officer, President and Director | ||||||||
| Matthew Rabinowitz | 426,434 | 0 | 10,383,434 | 0 | 473,514 | 0 | 0 | 11,283,382 |
| Executive Chairman | ||||||||
| Michael Brophy | 562,794 | 0 | 4,500,844 | 0 | 390,175 | 0 | 6,209 | 5,460,022 |
| Chief Financial Officer | ||||||||
| Solomon Moshkevich | 504,652 | 0 | 4,500,844 | 0 | 351,604 | 0 | 9,900 | 5,367,000 |
| President, Clinical Diagnostics | ||||||||
| John Fesko | 504,652 | 0 | 4,186,634 | 0 | 351,604 | 0 | 9,900 | 5,052,790 |
| President, Chief Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Steven Chapman | $14,957,319 | $13,032,674 | — | +1,924,645 |
| Matthew Rabinowitz | 11,283,382 | 9,834,129 | — | +1,449,253 |
| Michael Brophy | 5,460,022 | 4,887,334 | — | +572,688 |
| Solomon Moshkevich | 5,367,000 | 4,888,856 | — | +478,144 |
| John Fesko | 5,052,790 | 4,888,856 | — | +163,934 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Roy Baynes | Director | 2026-04-24 | A | 83 | — | — | Common | Form 4 ↗ |
| Rowan E. Chapman | Director | 2026-04-24 | A | 222 | — | — | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-04-24 | A | 132 | — | — | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-04-24 | A | 222 | — | — | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-04-24 | A | 108 | — | — | Common | Form 4 ↗ |
| Brinkley Ruth Williams | Director | 2026-04-24 | A | 86 | — | — | Common | Form 4 ↗ |
| Rowan E. Chapman | Director | 2026-04-24 | A | 114 | — | — | Common | Form 4 ↗ |
| Herm Rosenman | Director | 2026-04-24 | A | 222 | — | — | Common | Form 4 ↗ |
| Eric H. Rubin | Director | 2026-04-24 | A | 5 | — | — | Common | Form 4 ↗ |
| Herm Rosenman | Director | 2026-04-24 | A | 117 | — | — | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-04-24 | A | 222 | — | — | Common | Form 4 ↗ |
| Monica Bertagnolli | Director | 2026-04-24 | A | 83 | — | — | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-04-27 | D | 771 | 204 | 157,091 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-04-27 | D | 2,266 | 196 | 444,623 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-04-27 | D | 988 | 204 | 201,937 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-04-27 | D | 200 | 197 | 39,452 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-04-27 | D | 285 | 204 | 58,069 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-04-27 | D | 188 | 204 | 38,425 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-04-27 | D | 873 | 204 | 177,874 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-04-27 | D | 1,185 | 204 | 242,202 | Common | Form 4 ↗ |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 2026-04-27 | D | 771 | 204 | 157,091 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-04-27 | D | 300 | 190 | 57,035 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-04-27 | D | 3,566 | 204 | 728,855 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-04-27 | D | 1,222 | 204 | 249,765 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-04-27 | D | 500 | 192 | 96,064 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-04-27 | D | 997 | 204 | 203,139 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-04-27 | D | 805 | 197 | 158,575 | Common | Form 4 ↗ |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 2026-04-27 | D | 917 | 204 | 187,426 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-04-27 | D | 2,272 | 204 | 462,920 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-04-27 | D | 1,070 | 195 | 208,460 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-04-27 | D | 1,000 | 194 | 193,779 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-05-01 | D | 482 | 210 | 101,456 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-01 | D | 405 | 206 | 83,495 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-01 | D | 107 | 206 | 22,059 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-01 | D | 505 | 203 | 102,674 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-01 | D | 520 | 202 | 104,832 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-05-01 | D | 313 | 206 | 64,528 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-01 | D | 400 | 205 | 82,123 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-05-01 | D | 902 | 206 | 185,956 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-01 | D | 560 | 201 | 112,533 | Common | Form 4 ↗ |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 2026-05-01 | D | 291 | 206 | 59,993 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-01 | D | 150 | 207 | 31,040 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-01 | D | 865 | 204 | 176,863 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-05-01 | D | 330 | 206 | 68,033 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-05-04 | D | 722 | 206 | 148,848 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-05-04 | A | 2,389 | — | — | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-05-04 | D | 2,887 | 207 | 596,945 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-05-04 | D | 1,454 | 241 | 350,981 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-05-04 | D | 1,697 | 207 | 350,889 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-05-04 | D | 948 | 205 | 194,549 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 200 | 205 | 41,086 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 96 | 199 | 19,146 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 30 | 203 | 6,085 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 290 | 203 | 58,749 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 85 | 200 | 16,959 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 285 | 203 | 57,765 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 200 | 210 | 41,915 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 900 | 207 | 186,517 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 700 | 208 | 145,690 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 345 | 201 | 69,384 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 9 | 203 | 1,830 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 360 | 201 | 72,429 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-05-08 | D | 1,150 | 210 | 241,897 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-05-26 | D | 1,652 | 203 | 335,091 | Common | Form 4 ↗ |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 2026-05-26 | D | 1,438 | 203 | 291,684 | Common | Form 4 ↗ |
| Eric H. Rubin | Director | 2026-05-29 | A | 2,124 | — | — | RSU | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-01 | D | 2,850 | 223 | 634,964 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-06-01 | D | 213 | 219 | 46,719 | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-01 | D | 14,885 | 222 | 3,298,290 | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-01 | D | 26,411 | 219 | 5,775,771 | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-01 | D | 2,450 | 224 | 548,375 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-06-01 | D | 413 | 219 | 90,383 | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-01 | D | 21,304 | 221 | 4,706,946 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-06-01 | D | 1,802 | 218 | 391,971 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-06-01 | D | 572 | 221 | 126,222 | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-01 | D | 10,100 | 220 | 2,219,746 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 2,503 | 213 | 534,250 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 6,751 | 226 | 1,526,720 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 1,742 | 218 | 380,252 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 832 | 212 | 176,732 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 1,300 | 215 | 279,279 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 2,351 | 217 | 510,260 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 2,758 | 219 | 604,224 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 1,443 | 224 | 323,101 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 1,630 | 225 | 366,737 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 5,499 | 216 | 1,188,523 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 2,400 | 220 | 528,450 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 3,409 | 227 | 773,740 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 2,006 | 222 | 445,827 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-06-04 | D | 6,500 | 223 | 1,451,680 | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-05 | D | 116 | 219 | 25,383 | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-05 | D | 3,174 | 218 | 692,276 | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-05 | D | 4,694 | 217 | 1,020,023 | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-05 | A | 11,000 | 23 | 251,130 | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-05 | D | 3,016 | 216 | 651,646 | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-05 | D | 11,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 7,182 | 217 | 1,554,959 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 5,034 | 213 | 1,074,399 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 3,161 | 215 | 680,815 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 831 | 210 | 174,372 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 10,338 | 215 | 2,219,747 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 400 | 219 | 87,489 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 1,237 | 212 | 262,008 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 6,741 | 217 | 1,461,540 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 3,267 | 210 | 687,048 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 2,957 | 212 | 625,737 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 3,811 | 218 | 829,284 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 4,276 | 217 | 929,278 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 5,097 | 213 | 1,084,827 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 11,877 | 216 | 2,564,338 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 2,536 | 209 | 531,280 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 2,133 | 218 | 465,357 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 12,142 | 212 | 2,577,402 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 5,707 | 214 | 1,223,301 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 1,605 | 219 | 352,070 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 1,832 | 211 | 386,057 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-06-12 | D | 7,836 | 214 | 1,676,000 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-15 | D | 300 | 214 | 64,061 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-15 | D | 500 | 212 | 106,212 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-15 | D | 1,750 | 210 | 368,011 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-15 | D | 600 | 211 | 126,803 | Common | Form 4 ↗ |
| Rowan E. Chapman | Director | 2026-06-16 | D | 2,964 | 217 | 642,536 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 244 | 221 | 54,037 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 301 | 221 | 66,637 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 96 | 219 | 21,037 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 122 | 221 | 26,953 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 256 | 218 | 55,843 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 71 | 220 | 15,653 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 267 | 218 | 58,253 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 15 | 222 | 3,332 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-06-17 | D | 128 | 219 | 28,065 | Common, indirect | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-06-24 | D | 11,130 | 253 | 2,820,213 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-06-24 | D | 16,204 | 250 | 4,055,036 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-06-24 | D | 1,200 | 252 | 301,915 | Common | Form 4 ↗ |
| Herm Rosenman | Director | 2026-06-24 | D | 16,530 | 250 | 4,132,500 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-06-24 | D | 5,066 | 252 | 1,278,190 | Common | Form 4 ↗ |
| Monica Bertagnolli | Director | 2026-06-26 | A | 75 | — | — | Common | Form 4 ↗ |
| Rowan E. Chapman | Director | 2026-06-26 | A | 1,571 | — | — | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-06-26 | A | 75 | — | — | Common | Form 4 ↗ |
| Rowan E. Chapman | Director | 2026-06-26 | A | 103 | — | — | Common | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-26 | A | 120 | — | — | Common | Form 4 ↗ |
| Roy Baynes | Director | 2026-06-26 | A | 1,571 | — | — | Common | Form 4 ↗ |
| Herm Rosenman | Director | 2026-06-26 | A | 1,571 | — | — | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-26 | A | 98 | — | — | Common | Form 4 ↗ |
| Herm Rosenman | Director | 2026-06-26 | A | 106 | — | — | Common | Form 4 ↗ |
| Gail Marcus | Director | 2026-06-26 | A | 1,571 | — | — | Common | Form 4 ↗ |
| Thomas J. Lynch Jr. | Director | 2026-06-26 | A | 1,905 | — | — | RSU | Form 4 ↗ |
| Roelof Botha | Director | 2026-06-26 | A | 1,571 | — | — | Common | Form 4 ↗ |
| Monica Bertagnolli | Director | 2026-06-26 | A | 1,571 | — | — | Common | Form 4 ↗ |
| Eric H. Rubin | Director | 2026-06-26 | A | 75 | — | — | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 1,100 | 275 | 302,717 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 1,955 | 278 | 543,973 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 3,705 | 268 | 993,330 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 1,568 | 267 | 418,331 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 1,932 | 269 | 519,694 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 500 | 274 | 137,095 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 1,357 | 271 | 367,699 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 454 | 272 | 123,551 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 1,400 | 276 | 386,740 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-07-01 | D | 100 | 267 | 26,719 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 484 | 270 | 130,616 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 300 | 279 | 83,630 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-01 | D | 2,045 | 277 | 567,056 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-07-01 | D | 2,600 | 273 | 709,774 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-07-01 | D | 300 | 274 | 82,218 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-07-06 | D | 1,000 | 280 | 280,000 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-13 | D | 500 | 267 | 133,377 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-13 | D | 450 | 268 | 120,475 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-13 | D | 400 | 265 | 106,060 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-13 | D | 500 | 268 | 134,194 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-13 | D | 800 | 264 | 211,436 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-13 | D | 500 | 263 | 131,358 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 100 | 274 | 27,368 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 80 | 276 | 22,081 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 180 | 275 | 49,497 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 170 | 275 | 46,795 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 390 | 273 | 106,473 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 450 | 273 | 122,871 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 40 | 276 | 11,055 | Common, indirect | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-15 | D | 90 | 274 | 24,683 | Common, indirect | Form 4 ↗ |
| Rowan E. Chapman | Director | 2026-07-15 | D | 135 | 275 | 37,101 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-07-27 | D | 1,010 | 260 | 263,096 | Common | Form 4 ↗ |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 2026-07-27 | D | 931 | 254 | 236,540 | Common | Form 4 ↗ |
| John Fesko | PRESIDENT, CHIEF BUS. OFFICER | 2026-07-27 | D | 782 | 260 | 203,704 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-07-27 | D | 2,190 | 260 | 570,475 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-07-27 | D | 1,863 | 249 | 464,595 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-07-27 | D | 782 | 260 | 203,704 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-27 | D | 191 | 254 | 48,527 | Common | Form 4 ↗ |
| Steven Leonard Chapman | Director | 2026-07-27 | D | 3,580 | 254 | 909,572 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-27 | D | 884 | 260 | 230,274 | Common | Form 4 ↗ |
| Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | 2026-07-27 | D | 1,204 | 254 | 305,901 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-07-27 | D | 1,008 | 254 | 255,797 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-07-27 | D | 1,241 | 254 | 315,301 | Common | Form 4 ↗ |
| Jonathan Sheena | Director | 2026-07-27 | D | 288 | 260 | 75,021 | Common | Form 4 ↗ |
| Michael Brophy | CHIEF FINANCIAL OFFICER | 2026-07-27 | D | 170 | 254 | 43,237 | Common | Form 4 ↗ |
| Matthew Rabinowitz | Director | 2026-07-27 | D | 1,718 | 260 | 447,523 | Common | Form 4 ↗ |
| Matthew Rabinowitz | SEC. AND CHIEF LEGAL OFFICER | 2026-07-27 | D | 1,003 | 254 | 254,833 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Solomon Moshkevich | RSU | 2025-01-17 | — | — | 12,720 | — | $2,250,422 |
| Michael Brophy | RSU | 2025-01-17 | — | — | 12,720 | — | 2,250,422 |
| Matthew Rabinowitz | PSU | 2025-01-17 | 14,673 | 29,345 | — | 58,690 | 5,191,717 |
| Steven Chapman | PSU | 2025-01-17 | 18,341 | 36,682 | — | 73,364 | 6,489,779 |
| John Fesko | RSU | 2025-01-17 | — | — | 11,832 | — | 2,093,317 |
| Steven Chapman | RSU | 2025-01-17 | — | — | 36,682 | — | 6,489,779 |
| Solomon Moshkevich | PSU | 2025-01-17 | 6,360 | 12,720 | — | 25,440 | 2,250,422 |
| Michael Brophy | PSU | 2025-01-17 | 6,360 | 12,720 | — | 25,440 | 2,250,422 |
| John Fesko | PSU | 2025-01-17 | 5,916 | 11,832 | — | 23,664 | 2,093,317 |
| Matthew Rabinowitz | RSU | 2025-01-17 | — | — | 29,345 | — | 5,191,717 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Solomon Moshkevich | $2,250,422 | $2,250,422 | $0 | 50.0% |
| Michael Brophy | 2,250,422 | 2,250,422 | 0 | 50.0% |
| Matthew Rabinowitz | 5,191,717 | 5,191,717 | 0 | 50.0% |
| Steven Chapman | 6,489,779 | 6,489,779 | 0 | 50.0% |
| John Fesko | 2,093,317 | 2,093,317 | 0 | 50.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chapman | PSU | 36,682 | — | $8,403,479 |
| Michael Brophy | PSU | 31,352 | — | 7,182,430 |
| John Fesko | PSU | 31,352 | — | 7,182,430 |
| Solomon Moshkevich | PSU | 31,352 | — | 7,182,430 |
| Michael Brophy | PSU | 12,720 | — | 2,914,025 |
| John Fesko | RSU | 11,832 | — | 2,710,593 |
| Michael Brophy | RSU | 17,636 | — | 4,040,231 |
| Solomon Moshkevich | RSU | 571 | — | 130,810 |
| John Fesko | RSU | 856 | — | 196,101 |
| Matthew Rabinowitz | Option | 183,172 | 43.74 | — |
| Chapman | PSU | 86,220 | — | 19,752,140 |
| Chapman | RSU | 152,718 | — | 34,986,167 |
| John Fesko | PSU | 40,000 | — | 9,163,600 |
| Michael Brophy | RSU | 1,522 | — | 348,675 |
| Matthew Rabinowitz | Option | 600,000 | 13.04 | — |
| Matthew Rabinowitz | Option | 425,000 | 10.41 | — |
| Matthew Rabinowitz | Option | 300,000 | 9.59 | — |
| Matthew Rabinowitz | Option | 257,000 | 25.46 | — |
| Matthew Rabinowitz | Option | 220,000 | 20.27 | — |
| Matthew Rabinowitz | Option | 217,708 | 65.47 | — |
| Matthew Rabinowitz | Option | 179,820 | 9.29 | — |
| Matthew Rabinowitz | Option | 220,000 | 94.14 | — |
| Matthew Rabinowitz | Option | 111,301 | 43.74 | — |
| Solomon Moshkevich | Option | 34,000 | 19.68 | — |
| Matthew Rabinowitz | Option | 20,180 | 10.29 | — |
| John Fesko | Option | 12,283 | 19.68 | — |
| Solomon Moshkevich | Option | 5,932 | 15.57 | — |
| Solomon Moshkevich | Option | 5,125 | 9.59 | — |
| John Fesko | Option | 1,804 | 9.29 | — |
| Matthew Rabinowitz | PSU | 68,976 | — | 15,801,712 |
| Matthew Rabinowitz | RSU | 38,799 | — | 8,888,463 |
| Solomon Moshkevich | Option | 42,500 | 10.41 | — |
| Solomon Moshkevich | RSU | 29,423 | — | 6,740,515 |
| Michael Brophy | RSU | 15,520 | — | 3,555,477 |
| John Fesko | RSU | 3,607 | — | 826,328 |
| Solomon Moshkevich | RSU | 3,206 | — | 734,463 |
| John Fesko | Option | 1,725 | 15.57 | — |
| Michael Brophy | RSU | 59,598 | — | 13,653,306 |
| Chapman | RSU | 48,499 | — | 11,110,636 |
| Solomon Moshkevich | RSU | 44,698 | — | 10,239,865 |
| John Fesko | RSU | 44,698 | — | 10,239,865 |
| Chapman | RSU | 36,682 | — | 8,403,479 |
| Matthew Rabinowitz | RSU | 29,345 | — | 6,722,646 |
| Matthew Rabinowitz | PSU | 29,345 | — | 6,722,646 |
| John Fesko | RSU | 17,636 | — | 4,040,231 |
| Michael Brophy | RSU | 12,720 | — | 2,914,025 |
| Solomon Moshkevich | RSU | 11,640 | — | 2,666,608 |
| Solomon Moshkevich | RSU | 17,636 | — | 4,040,231 |
| Solomon Moshkevich | PSU | 12,720 | — | 2,914,025 |
| John Fesko | RSU | 11,640 | — | 2,666,608 |
| Solomon Moshkevich | RSU | 12,720 | — | 2,914,025 |
| John Fesko | PSU | 11,832 | — | 2,710,593 |
| Chapman | RSU | 39,771 | — | 9,111,138 |
| Solomon Moshkevich | Option | 20,000 | 9.29 | — |
| Chapman | RSU | 3,386 | — | 775,699 |
The primary objectives of our executive compensation program are to: Reward the achievement of specified performance goals (pay for performance); Align our executive officers interests with those of our stockholders through long-term incentives linked to revenue growth and enhancement of stockholder value that also facilitate executive retention; Attract, retain and motivate superior executive talent with market competitive compensation
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 119,883,700 | 2,492,978 | 343,875 | 97.96% | Passed |
| 2025 | 2025-06-12 | 107,796,630 | 4,604,390 | 147,007 | 95.9% | Passed |
| 2024 | 2024-06-12 | 101,567,539 | 5,854,068 | 60,358 | 94.55% | Passed |
| 2023 | 2023-06-09 | 88,588,552 | 4,729,453 | 86,259 | 94.93% | Passed |
| 2022 | 2022-05-25 | 39,574,100 | 36,870,671 | 66,564 | 51.77% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 97.96%a |
| 2025 | 2025-06-12 | 95.9%b |
| 2024 | 2024-06-12 | 94.55%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of this proposal, other than counting towards the quorum of the meeting.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not affect the outcome of this proposal, other than counting towards the quorum of the meeting.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 101 : 1 |
|---|---|
| CEO total compensation | $14,957,319 |
| Median employee compensation | $148,726 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Roelof BothaIndependent · Lead Independent Director · Nominating, Corporate Governance and Compliance Committee | $28,451 | $485,013 | $0 | $0 | $1 | $513,465 |
| Herm RosenmanIndependent · Audit Committee (Chair) · Human Capital Committee | 25,222 | 475,849 | 0 | 0 | -1 | 501,070 |
| Rowan ChapmanIndependent · Audit Committee · Human Capital Committee (Chair) | 23,125 | 474,035 | 0 | 0 | 0 | 497,160 |
| Gail MarcusIndependent · Audit Committee · Nominating, Corporate Governance and Compliance Committee (Chair) | 21,875 | 470,145 | 0 | 0 | 0 | 492,020 |
| Monica BertagnolliIndependent · Nominating, Corporate Governance and Compliance Committee · Newly elected | 4,688 | 463,797 | 0 | 0 | -1 | 468,484 |
| Ruth Williams-BrinkleyIndependent · Human Capital Committee | 17,500 | 411,665 | 0 | 0 | 0 | 429,165 |
| Roy BaynesIndependent · Nominating, Corporate Governance and Compliance Committee | 17,840 | 409,620 | 0 | 0 | -1 | 427,459 |
| James HealyIndependent · Audit Committee · Human Capital Committee | 21,838 | 0 | 0 | 0 | 0 | 21,838 |
| Steven ChapmanEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Matthew RabinowitzEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Jonathan SheenaNot independent | 0 | 0 | 0 | 0 | 0 | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $45,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 15,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $160,539 |
| Equity awards (grant-date value) | $3,190,124 |
| All other compensation | $-2 |
| Total cost of the board | $3,350,661 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Natera names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Natera.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corp. | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 4 | Insulet Corp. | 2025 | Ashley McEvoy | 729,808 | 12,958,850 | 2,999,913 | 2,031,562 | 18,858,968 |
| 5 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 6 | Qualys, Inc. | 2025 | Sumedh Thakar | 616,167 | 14,597,565 | 0 | 723,377 | 15,947,158 |
| 7 | Masimo Corporation | 2024 | Joe Kiani | 1,209,181 | 10,259,983 | 3,420,105 | 0 | 15,932,345 |
| 8 | Exact Sciences Corporation | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 9 | Natera | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 10 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 11 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 12 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 13 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 14 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 15 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 16 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 17 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 18 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Natera | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Options 25 | No | Pay Governance |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon Talent |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exact Sciences Corporation | 47% | PSU 60 · RSU 40 | No | Aon |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Incyte Corp. | 138.6% | PSU 60 · Options 20 · RSU 20 | Yes — relative total shareholder return (TSR) | Aon |
| Insulet Corp. | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| Ionis Pharmaceuticals, Inc. | 228% | RSU 67 · PSU 33 | Yes — Relative TSR | Aon Human Capital Solutions |
| Masimo Corporation | 134% | PSU 75 · Options 25 | Yes — Three-Year Cumulative Relative TSR | FW Cook |
| Neurocrine Biosciences, Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Qualys, Inc. | not disclosed | not disclosed | No | Compensia, Inc. |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Sarepta Therapeutics, Inc. | 100% | RSU 50 · PSU 50 | No | FW Cook |
| United Therapeutics Corporation | 221% | Options 50 · PSU 50 | No | Aon Human Capital Solutions |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Steven Chapman | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Summary Compensation Table” · page 59. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 2 | Section 01, Matthew Rabinowitz | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Summary Compensation Table” · page 59. As printed: 11,283,382. Filing ↗machine: t190 · r15 · c14 · span 1310282–1310292 |
| 3 | Section 01, Michael Brophy | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Summary Compensation Table” · page 59. As printed: 5,460,022. Filing ↗machine: t190 · r8 · c14 · span 1281669–1281678 |
| 4 | Section 01, Solomon Moshkevich | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Summary Compensation Table” · page 59. As printed: 5,367,000. Filing ↗machine: t190 · r13 · c14 · span 1302120–1302129 |
| 5 | Section 01, John Fesko | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Summary Compensation Table” · page 59. As printed: 5,052,790. Filing ↗machine: t190 · r11 · c14 · span 1293825–1293834 |
| 6 | Section 03, Solomon Moshkevich RSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r7 · c6 · span 1095008–1095014 |
| 7 | Section 03, Michael Brophy RSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r5 · c6 · span 1089264–1089270 |
| 8 | Section 03, Matthew Rabinowitz PSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r8 · c6 · span 1097908–1097914 |
| 9 | Section 03, Steven Chapman PSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r4 · c6 · span 1086411–1086417 |
| 10 | Section 03, John Fesko RSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r6 · c6 · span 1092151–1092157 |
| 11 | Section 03, Steven Chapman RSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r4 · c6 · span 1086411–1086417 |
| 12 | Section 03, Solomon Moshkevich PSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r7 · c6 · span 1095008–1095014 |
| 13 | Section 03, Michael Brophy PSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r5 · c6 · span 1089264–1089270 |
| 14 | Section 03, John Fesko PSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r6 · c6 · span 1092151–1092157 |
| 15 | Section 03, Matthew Rabinowitz RSU | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t173 · r8 · c6 · span 1097908–1097914 |
| 16 | Section 07, pay ratio | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “CEO Pay Ratio”. As printed: 101 : 1. Filing ↗machine: span 2026961–2026964 |
| 17 | Section 08, Roelof Botha | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 513,465. Filing ↗machine: t109 · r6 · c6 · span 692480–692487 |
| 18 | Section 08, Herm Rosenman | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 501,070. Filing ↗machine: t109 · r10 · c6 · span 699645–699652 |
| 19 | Section 08, Rowan Chapman | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 497,160. Filing ↗machine: t109 · r7 · c6 · span 694206–694213 |
| 20 | Section 08, Gail Marcus | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 492,020. Filing ↗machine: t109 · r9 · c6 · span 697786–697793 |
| 21 | Section 08, Monica Bertagnolli | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 468,484. Filing ↗machine: t109 · r5 · c6 · span 690622–690629 |
| 22 | Section 08, Ruth Williams-Brinkley | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 429,165. Filing ↗machine: t109 · r11 · c6 · span 701454–701461 |
| 23 | Section 08, Roy Baynes | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 427,459. Filing ↗machine: t109 · r4 · c6 · span 688892–688899 |
| 24 | Section 08, James Healy | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 21,838. Filing ↗machine: t109 · r8 · c2 · span 694924–694930 |
| 25 | Section 08, Steven Chapman | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 26 | Section 08, Matthew Rabinowitz | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 27 | Section 08, Jonathan Sheena | DEF 14A | 2026-04-23 | 0001104659-26-047770 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 28 | Section 02, Roy Baynes 2026-04-24 | Form 4 | 2026-04-28 | 0001680739-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Rowan E. Chapman 2026-04-24 | Form 4 | 2026-04-28 | 0001786240-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Roelof Botha 2026-04-24 | Form 4 | 2026-04-28 | 0001222287-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Roelof Botha 2026-04-24 | Form 4 | 2026-04-28 | 0001222287-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Gail Marcus 2026-04-24 | Form 4 | 2026-04-28 | 0001702176-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Brinkley Ruth Williams 2026-04-24 | Form 4 | 2026-04-28 | 0001344381-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Rowan E. Chapman 2026-04-24 | Form 4 | 2026-04-28 | 0001786240-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Herm Rosenman 2026-04-24 | Form 4 | 2026-04-28 | 0001230057-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Eric H. Rubin 2026-04-24 | Form 4 | 2026-04-28 | 0001867204-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Herm Rosenman 2026-04-24 | Form 4 | 2026-04-28 | 0001230057-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Gail Marcus 2026-04-24 | Form 4 | 2026-04-28 | 0001702176-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Monica Bertagnolli 2026-04-24 | Form 4 | 2026-04-28 | 0001761030-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Michael Brophy 2026-04-27 | Form 4 | 2026-04-29 | 0001697362-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Jonathan Sheena 2026-04-27 | Form 4 | 2026-04-29 | 0001646649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Matthew Rabinowitz 2026-04-27 | Form 4 | 2026-04-29 | 0001857843-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Michael Brophy 2026-04-27 | Form 4 | 2026-04-29 | 0001697362-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Jonathan Sheena 2026-04-27 | Form 4 | 2026-04-29 | 0001646649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Jonathan Sheena 2026-04-27 | Form 4 | 2026-04-29 | 0001646649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Matthew Rabinowitz 2026-04-27 | Form 4 | 2026-04-29 | 0001857843-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Solomon Moshkevich 2026-04-27 | Form 4 | 2026-04-29 | 0002010019-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, John Fesko 2026-04-27 | Form 4 | 2026-04-29 | 0002010135-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Michael Brophy 2026-04-27 | Form 4 | 2026-04-29 | 0001697362-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Steven Leonard Chapman 2026-04-27 | Form 4 | 2026-04-29 | 0001711968-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Michael Brophy 2026-04-27 | Form 4 | 2026-04-29 | 0001697362-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Michael Brophy 2026-04-27 | Form 4 | 2026-04-29 | 0001697362-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Solomon Moshkevich 2026-04-27 | Form 4 | 2026-04-29 | 0002010019-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Jonathan Sheena 2026-04-27 | Form 4 | 2026-04-29 | 0001646649-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, John Fesko 2026-04-27 | Form 4 | 2026-04-29 | 0002010135-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Steven Leonard Chapman 2026-04-27 | Form 4 | 2026-04-29 | 0001711968-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Michael Brophy 2026-04-27 | Form 4 | 2026-04-29 | 0001697362-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Michael Brophy 2026-04-27 | Form 4 | 2026-04-29 | 0001697362-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Michael Brophy 2026-05-01 | Form 4 | 2026-05-05 | 0001697362-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Solomon Moshkevich 2026-05-01 | Form 4 | 2026-05-05 | 0002010019-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Jonathan Sheena 2026-05-01 | Form 4 | 2026-05-05 | 0001646649-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Solomon Moshkevich 2026-05-01 | Form 4 | 2026-05-05 | 0002010019-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Solomon Moshkevich 2026-05-01 | Form 4 | 2026-05-05 | 0002010019-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Michael Brophy 2026-05-01 | Form 4 | 2026-05-05 | 0001697362-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Solomon Moshkevich 2026-05-01 | Form 4 | 2026-05-05 | 0002010019-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Steven Leonard Chapman 2026-05-01 | Form 4 | 2026-05-05 | 0001711968-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Solomon Moshkevich 2026-05-01 | Form 4 | 2026-05-05 | 0002010019-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, John Fesko 2026-05-01 | Form 4 | 2026-05-05 | 0002010135-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Solomon Moshkevich 2026-05-01 | Form 4 | 2026-05-05 | 0002010019-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Solomon Moshkevich 2026-05-01 | Form 4 | 2026-05-05 | 0002010019-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Matthew Rabinowitz 2026-05-01 | Form 4 | 2026-05-05 | 0001857843-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Matthew Rabinowitz 2026-05-04 | Form 4 | 2026-05-06 | 0001646382-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Matthew Rabinowitz 2026-05-04 | Form 4 | 2026-05-06 | 0001646382-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Matthew Rabinowitz 2026-05-04 | Form 4 | 2026-05-06 | 0001646382-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Matthew Rabinowitz 2026-05-04 | Form 4 | 2026-05-06 | 0001646382-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Matthew Rabinowitz 2026-05-04 | Form 4 | 2026-05-06 | 0001646382-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Matthew Rabinowitz 2026-05-04 | Form 4 | 2026-05-06 | 0001646382-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Jonathan Sheena 2026-05-08 | Form 4 | 2026-05-15 | 0001646649-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Solomon Moshkevich 2026-05-26 | Form 4 | 2026-05-28 | 0002010019-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, John Fesko 2026-05-26 | Form 4 | 2026-05-28 | 0002010135-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Eric H. Rubin 2026-05-29 | Form 4 | 2026-06-03 | 0001867204-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Roelof Botha 2026-06-01 | Form 4 | 2026-06-03 | 0001222287-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Solomon Moshkevich 2026-06-01 | Form 4 | 2026-06-03 | 0002010019-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Roelof Botha 2026-06-01 | Form 4 | 2026-06-03 | 0001222287-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Roelof Botha 2026-06-01 | Form 4 | 2026-06-03 | 0001222287-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Roelof Botha 2026-06-01 | Form 4 | 2026-06-03 | 0001222287-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Solomon Moshkevich 2026-06-01 | Form 4 | 2026-06-03 | 0002010019-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Roelof Botha 2026-06-01 | Form 4 | 2026-06-03 | 0001222287-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Solomon Moshkevich 2026-06-01 | Form 4 | 2026-06-03 | 0002010019-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Solomon Moshkevich 2026-06-01 | Form 4 | 2026-06-03 | 0002010019-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Roelof Botha 2026-06-01 | Form 4 | 2026-06-03 | 0001222287-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Steven Leonard Chapman 2026-06-04 | Form 4 | 2026-06-05 | 0001711968-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Gail Marcus 2026-06-05 | Form 4 | 2026-06-09 | 0001702176-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Gail Marcus 2026-06-05 | Form 4 | 2026-06-09 | 0001702176-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Gail Marcus 2026-06-05 | Form 4 | 2026-06-09 | 0001702176-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Gail Marcus 2026-06-05 | Form 4 | 2026-06-09 | 0001702176-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Gail Marcus 2026-06-05 | Form 4 | 2026-06-09 | 0001702176-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Gail Marcus 2026-06-05 | Form 4 | 2026-06-09 | 0001702176-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Matthew Rabinowitz 2026-06-12 | Form 4 | 2026-06-16 | 0001646382-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Jonathan Sheena 2026-06-15 | Form 4 | 2026-06-17 | 0001646649-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Jonathan Sheena 2026-06-15 | Form 4 | 2026-06-17 | 0001646649-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Jonathan Sheena 2026-06-15 | Form 4 | 2026-06-17 | 0001646649-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Jonathan Sheena 2026-06-15 | Form 4 | 2026-06-17 | 0001646649-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Rowan E. Chapman 2026-06-16 | Form 4 | 2026-06-17 | 0001786240-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Jonathan Sheena 2026-06-17 | Form 4 | 2026-06-22 | 0001646649-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Matthew Rabinowitz 2026-06-24 | Form 4 | 2026-06-26 | 0001857843-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Matthew Rabinowitz 2026-06-24 | Form 4 | 2026-06-26 | 0001857843-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Matthew Rabinowitz 2026-06-24 | Form 4 | 2026-06-26 | 0001857843-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Herm Rosenman 2026-06-24 | Form 4 | 2026-06-26 | 0001230057-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Matthew Rabinowitz 2026-06-24 | Form 4 | 2026-06-26 | 0001857843-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Monica Bertagnolli 2026-06-26 | Form 4 | 2026-06-30 | 0001761030-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Rowan E. Chapman 2026-06-26 | Form 4 | 2026-06-30 | 0001786240-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Roy Baynes 2026-06-26 | Form 4 | 2026-06-30 | 0001680739-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Rowan E. Chapman 2026-06-26 | Form 4 | 2026-06-30 | 0001786240-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Roelof Botha 2026-06-26 | Form 4 | 2026-06-30 | 0001222287-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Roy Baynes 2026-06-26 | Form 4 | 2026-06-30 | 0001680739-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Herm Rosenman 2026-06-26 | Form 4 | 2026-06-30 | 0001230057-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Gail Marcus 2026-06-26 | Form 4 | 2026-06-30 | 0001702176-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Herm Rosenman 2026-06-26 | Form 4 | 2026-06-30 | 0001230057-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Gail Marcus 2026-06-26 | Form 4 | 2026-06-30 | 0001702176-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Thomas J. Lynch Jr. 2026-06-26 | Form 4 | 2026-06-30 | 0001474056-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Roelof Botha 2026-06-26 | Form 4 | 2026-06-30 | 0001222287-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Monica Bertagnolli 2026-06-26 | Form 4 | 2026-06-30 | 0001761030-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Eric H. Rubin 2026-06-26 | Form 4 | 2026-06-30 | 0001867204-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Solomon Moshkevich 2026-07-01 | Form 4 | 2026-07-06 | 0002010019-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Matthew Rabinowitz 2026-07-01 | Form 4 | 2026-07-06 | 0001857843-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Solomon Moshkevich 2026-07-01 | Form 4 | 2026-07-06 | 0002010019-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Solomon Moshkevich 2026-07-01 | Form 4 | 2026-07-06 | 0002010019-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Matthew Rabinowitz 2026-07-06 | Form 4 | 2026-07-08 | 0001646382-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Jonathan Sheena 2026-07-13 | Form 4 | 2026-07-15 | 0001646649-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Jonathan Sheena 2026-07-13 | Form 4 | 2026-07-15 | 0001646649-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Jonathan Sheena 2026-07-13 | Form 4 | 2026-07-15 | 0001646649-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Jonathan Sheena 2026-07-13 | Form 4 | 2026-07-15 | 0001646649-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Jonathan Sheena 2026-07-13 | Form 4 | 2026-07-15 | 0001646649-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Jonathan Sheena 2026-07-13 | Form 4 | 2026-07-15 | 0001646649-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Jonathan Sheena 2026-07-15 | Form 4 | 2026-07-17 | 0001646649-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Rowan E. Chapman 2026-07-15 | Form 4 | 2026-07-17 | 0001786240-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Solomon Moshkevich 2026-07-27 | Form 4 | 2026-07-29 | 0002010019-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, John Fesko 2026-07-27 | Form 4 | 2026-07-29 | 0002010135-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, John Fesko 2026-07-27 | Form 4 | 2026-07-29 | 0002010135-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Steven Leonard Chapman 2026-07-27 | Form 4 | 2026-07-29 | 0001711968-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Michael Brophy 2026-07-27 | Form 4 | 2026-07-29 | 0001697362-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Michael Brophy 2026-07-27 | Form 4 | 2026-07-29 | 0001697362-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Jonathan Sheena 2026-07-27 | Form 4 | 2026-07-29 | 0001646649-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Steven Leonard Chapman 2026-07-27 | Form 4 | 2026-07-29 | 0001711968-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, Matthew Rabinowitz 2026-07-27 | Form 4 | 2026-07-29 | 0001857843-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Solomon Moshkevich 2026-07-27 | Form 4 | 2026-07-29 | 0002010019-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Michael Brophy 2026-07-27 | Form 4 | 2026-07-29 | 0001697362-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, Michael Brophy 2026-07-27 | Form 4 | 2026-07-29 | 0001697362-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 02, Jonathan Sheena 2026-07-27 | Form 4 | 2026-07-29 | 0001646649-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 222 | Section 02, Michael Brophy 2026-07-27 | Form 4 | 2026-07-29 | 0001697362-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 223 | Section 02, Matthew Rabinowitz 2026-07-27 | Form 4 | 2026-07-29 | 0001646382-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 224 | Section 02, Matthew Rabinowitz 2026-07-27 | Form 4 | 2026-07-29 | 0001857843-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 225 | Section 06, 2026 vote | Form 8-K | 2026-06-16 | 0001604821-26-000003 | Item 5.07 · say-on-pay result. As reported: 97.96% (votes for as printed: 119,883,700). Filing ↗ |
| 226 | Section 06, 2025 vote | Form 8-K | 2025-06-18 | 0001104659-25-060626 | Item 5.07 · say-on-pay result. As reported: 95.9% (votes for as printed: 107,796,630). Filing ↗ |
| 227 | Section 06, 2024 vote | Form 8-K | 2024-06-18 | 0001104659-24-072800 | Item 5.07 · say-on-pay result. As reported: 94.55% (votes for as printed: 101,567,539). Filing ↗ |
| 228 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 229 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 230 | Section 09b board cost (computed) | Computed | — | computed | Cash 160,539 + equity 3,190,124 + all other -2 = 3,350,661, summed across the director compensation table rows.machine: formula: Σ = 3,350,661 |
| 231 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 232 | Incyte Corp., Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corp.'s own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 233 | BioMarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 234 | Insulet Corp., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013333 | CEO total compensation as printed in Insulet Corp.'s own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087 |
| 235 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 236 | Qualys, Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001140361-26-016101 | CEO total compensation as printed in Qualys, Inc.'s own proxy. As printed: 15,947,158. Filing ↗machine: t212 · r2 · c19 · span 828448–828458 |
| 237 | Masimo Corporation, Section 10b CEO total | DEF 14A | 2025-03-26 | 0001104659-25-027887 | CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 15,932,345. Filing ↗machine: span 1265493–1265503 |
| 238 | Exact Sciences Corporation, Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences Corporation's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 239 | Natera (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 240 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 241 | Revvity, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295 |
| 242 | Neurocrine Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 243 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗machine: t325 · r3 · c25 · span 1543650–1543661 |
| 244 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 245 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 246 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 247 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: t34 · r2 · c25 · span 1454395–1454404 |
| 248 | Repligen Corporation, Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140115 | CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. Filing ↗machine: t16 · r4 · c2 · span 577065–577074 |
| 249 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc. names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 250 | Section 10a, Revvity, Inc. reciprocity | DEF 14A | — | 0001193125-26-107266 | Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 251 | Section 10a, Masimo Corporation reciprocity | DEF 14A | — | 0001104659-25-027887 | Masimo Corporation's most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 252 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 253 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc. names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 254 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 255 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation's most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 256 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 257 | Section 10a, BioMarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 258 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 259 | Section 10a, Neurocrine Biosciences, Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 260 | Section 10a, Exact Sciences Corporation reciprocity | DEF 14A | — | 0001124140-25-000034 | Exact Sciences Corporation names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 261 | Section 10a, Repligen Corporation reciprocity | DEF 14A | — | 0001193125-26-140115 | Repligen Corporation names Natera in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 262 | Section 10a, Qualys, Inc. reciprocity | DEF 14A | — | 0001140361-26-016101 | Qualys, Inc.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |
| 263 | Section 10a, Insulet Corp. reciprocity | DEF 14A | — | 0001140361-26-013333 | Insulet Corp.'s most recent proxy was read; its disclosed peer group does not include Natera. Filing ↗ |